Latest Breaking News On - Neuromuscular disease center - Page 1 : comparemela.com

Company s lead drug candidate PrimeC is currently being evaluated in a Phase IIb trial, with topline data expected in mid-2023CAMBRIDGE, Mass., Se.

United statesUniversity of arizonaUnited kingdomSan franciscoJeremy shefnerCantor fitzgeraldGregoryw fultonCharles duncanClinical trials consortiumDepartment of neurologyBarrow neurological instituteDrug administrationCantor healthcare teamNeurosense therapeutics ltdNeuromuscular disease centerEuropean medicines agency